|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300074396 |
|
最近更新日期: Date of Last Refreshed on: |
2023-08-04 17:46:21 |
|
注册时间: Date of Registration: |
2023-08-04 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
哌柏西利联合维奈克拉、阿扎胞苷方案(VAP方案)治疗NUP98-R阳性儿童急性髓细胞白血病的单臂、开放性、多中心临床研究 |
|
Public title: |
A single-arm, open, multicenter clinical study of Palbociclib in combination with Venetoclax and Azacitidine regimen (VAP regimen) for the treatment of NUP98-R positive childhood acute myeloid leukemia |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
哌柏西利联合维奈克拉、阿扎胞苷方案(VAP方案)治疗NUP98-R阳性儿童急性髓细胞白血病的单臂、开放性、多中心临床研究 |
|
Scientific title: |
A single-arm, open, multicenter clinical study of Palbociclib in combination with Venetoclax and Azacitidine regimen (VAP regimen) for the treatment of NUP98-R positive childhood acute myeloid leukemia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈鸿博 |
研究负责人: |
金润铭 |
|
Applicant: |
Chen Hongbo |
Study leader: |
Runming Jin |
|
申请注册联系人电话: Applicant telephone: |
+86 27 8535 0744 |
研究负责人电话: Study leader's telephone: |
+86 27 8535 0744 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hbchen@hust.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
jinrunm@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖北省武汉市解放大道1277号 |
研究负责人通讯地址: |
湖北省武汉市解放大道1277号 |
|
Applicant address: |
No. 1277 Jiefang Avenue, Wuhan, Hubei |
Study leader's address: |
No. 1277 Jiefang Avenue, Wuhan, Hubei |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
华中科技大学同济医学院附属协和医院 |
||
|
Applicant's institution: |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
研究负责人所在单位: |
华中科技大学同济医学院附属协和医院 |
||
|
Affiliation of the Leader: |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
【2022】论审字(0526-02)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
华中科技大学同济医学院附属协和医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-12-02 00:00:00 |
||
|
伦理委员会联系人: |
褚圆圆 |
||
|
Contact Name of the ethic committee: |
Chu Yuanyuan |
||
|
伦理委员会联系地址: |
湖北省武汉市解放大道1277号 |
||
|
Contact Address of the ethic committee: |
No. 1277 Jiefang Avenue, Wuhan, Hubei |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 8572 6375 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
华中科技大学同济医学院附属协和医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市解放大道1277号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1277 Jiefang Avenue, Wuhan, Hubei |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海市儿童健康基金会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Children's Health Foundation |
||||||||||||||||||||||
|
Target disease: |
acute myelocytic leukemia |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期+II期 | ||||||||||||||||||||||
|
Study phase: |
1-2 |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
评价哌柏西利联合维奈克拉、阿扎胞苷方案(VAP方案)治疗NUP98-R阳性儿童急性髓细胞白血病的有效性和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy and safety of Palbociclib in combination with Venetoclax and Azacitidine regimen (VAP regimen) in the treatment of NUP98-R positive childhood acute myeloid leukemia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、明确诊断为急性髓系白血病; |
||||||||||||||||||||||
|
Inclusion criteria |
1.A clear diagnosis of AML. |
||||||||||||||||||||||
|
排除标准: |
1、急性早幼粒细胞白血病; 2、MDS转化的AML; 3、范可尼贫血继发的AML; 4、Kostmanne综合征继发的AML; 5、Shwachman综合征继发的AML; 6、其他骨髓衰竭性疾病继发的AML; 7、只做暂时性化疗或免疫治疗,而不接受按照治疗方案进行系统治疗; 8、具有任何显著异常的并存疾病或精神疾病,影响病人的生命安全及依从性,影响知情同意、研究参与、随访或结果解释 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Acute promyelocytic leukemia. 2.AML transformed by MDS. 3.AML secondary to Fanconi anemia. 4.AML secondary to Kostmanne's syndrome. 5.AML secondary to Shwachman syndrome. 6.AML secondary to other bone marrow failure disorders. 7.Only temporary chemotherapy or immunotherapy, without receiving systemic treatment in accordance with the treatment protocol. 8.With any significant abnormalities of coexisting diseases or psychiatric disorders that affect the patient's life safety and compliance, informed consent, study participation, follow-up or interpretation of result |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-01-21 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究为单臂试验,无需采用随机方法 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
No randomised method was required for this single-arm study |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
临床试验公共管理平台(http://www.medresman.org.cn/uc/project/projectlistauthor.aspx) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Clinical Trial Management Public Platform(http://www.medresman.org.cn/uc/project/projectlistauthor.aspx) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集和管理采用病历记录表和专人管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection and management adopts medical record form and special personnel management |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |